ライフサイエンスコーパス: reflux disease

1 evant to the association between obesity and reflux disease.

2 formed surgical therapy for gastroesophageal reflux disease.

3 vel potential treatment for gastroesophageal reflux disease.

4 ently overlap with those of gastroesophageal reflux disease.

5 cribed for the treatment of gastroesophageal reflux disease.

6 ormation, 11 (41%) had objective evidence of reflux disease.

7 the presence of concomitant gastroesophageal reflux disease.

8 vely distinguishing it from gastroesophageal reflux disease.

9 to those of patients with gastro-oesophageal reflux disease.

10 an effective treatment for gastroesophageal reflux disease.

11 ognized disease that mimics gastroesophageal reflux disease.

12 rritable bowel syndrome and gastroesophageal reflux disease.

13 developing complications of gastroesophageal reflux disease.

14 ease commonly confused with gastroesophageal reflux disease.

15 disorders and treatment of gastroesophageal reflux disease.

16 between BMI and symptoms of gastroesophageal reflux disease.

17 iologic system is perturbed in subjects with reflux disease.

18 ccurrence and management of gastroesophageal reflux disease.

19 s are at increased risk for gastroesophageal reflux disease.

20 dicative of severe types of gastroesophageal reflux disease.

21 ts with symptomatic GERD do not have erosive reflux disease.

22 and a reliable indicator of gastroesophageal reflux disease.

23 e research and treatment of gastroesophageal reflux disease.

24 l ulcer, gastric ulcer, and gastroesophageal reflux disease.

25 esophagus or other types of gastroesophageal reflux disease.

26 commonly associated with gastro-oesophageal reflux disease.

27 heartburn in patients with gastro-esophageal reflux disease.

28 formed for the treatment of gastroesophageal reflux disease.

29 ients with mild-to-moderate gastroesophageal reflux disease.

30 and stricture secondary to gastroesophageal reflux disease.

31 ardia are manifestations of gastroesophageal reflux disease.

32 cinoma are complications of gastroesophageal reflux disease.

33 ure by waist belt on reflux in patients with reflux disease.

34 o clear and buffer the refluxate, leading to reflux disease.

35 long-lasting treatment for gastroesophageal reflux disease.

36 s associated with a risk of gastroesophageal reflux disease.

37 in pediatric patients with gastroesophageal reflux disease.

38 r the surgical treatment of gastroesophageal reflux disease.

39 5%), constipation (13%) and gastroesophageal reflux disease (12%).

40 , hypertension (21.9%), and gastroesophageal reflux disease (17.3%).

41 The presence of gastroesophageal reflux disease (26%), esophageal stricture (39%), or bot

42 nusitis 42.3% (5870), and gastro-oesophageal reflux disease 39.3% (5650).

43 0%), sinusitis (47.8%), and gastroesophageal reflux disease (46.3%).

44 pnea may be associated with gastroesophageal reflux disease, a strong risk factor for Barrett's esoph

45 , chronic rhinitis, asthma, gastroesophageal reflux disease, adenotonsillitis, sleep apnea, anxiety,

46 factors evaluated included gastroesophageal reflux disease, alcohol consumption, smoking, chronic op

47 a complication of chronic gastro-oesophageal reflux disease, although asymptomatic individuals might

48 and duration of symptoms of gastroesophageal reflux disease among randomly selected participants in t

49 -nine subjects were identified as nonerosive reflux disease and 17 as erosive esophagitis.

50 quality of life related to gastroesophageal reflux disease and a 50% or greater reduction in the use

51 of peptic ulcer disease and gastrosophageal reflux disease and acts by irreversibly blocking ATP4A,

52 ecreased prevalence of both gastroesophageal reflux disease and adenocarcinoma of the esophagus and c

53 The incidence of gastro-oesophageal reflux disease and Barrett's oesophagus is increasing.

54 niques in the management of gastroesophageal reflux disease and constipation also may have an impact

55 psies of patients with EoE, gastroesophageal reflux disease and controls.

56 ties is similar except for gastro-esophageal reflux disease and dyslipidemia that appear to be more s

57 both procedures except for gastro-esophageal reflux disease and dyslipidemia, which were more success

58 ged 18 years and older with gastroesophageal reflux disease and erosive esophagitis.

59 evolving definition and its relationship to reflux disease and functional gastrointestinal disorders

60 rformed in 758 patients for gastroesophageal reflux disease and in 99 for paraesophageal hernia.

61 osis, including the role of gastroesophageal reflux disease and proton pump inhibitor-responsive esop

62 e to design new surgical strategies to treat reflux disease and reduce complications of fundoplicatio

63 The potential roles of undiagnosed venous reflux disease and the military physical training enviro

64 Approximately 20% have gastro-oesophageal reflux disease and this can be effectively treated with

65 n with a medical history of gastroesophageal reflux disease and type II diabetes presented to the hos

66 acid reflux in cough due to gastroesophageal reflux disease, and 3) developing reliable and reproduci

67 of dyspnea, 87 percent had gastroesophageal reflux disease, and 54 percent had nasal congestion.

68 eep-disordered breathing, gastro-oesophageal reflux disease, and anxiety or depression.

69 ma, mechanical ventilation, gastroesophageal reflux disease, and aspiration or other types of pneumon

70 ological manifestation of gastro-oesophageal reflux disease, and is a major risk factor for the devel

71 r diagnoses (eg, pneumonia, gastroesophageal reflux disease, and other comorbidities).

72 o irritable bowel syndrome, gastroesophageal reflux disease, and peptic ulcer disease.

73 isk factor for oesophageal adenocarcinoma is reflux disease, and the rising incidence of this coincid

74 is usually due to asthma, gastro-oesophageal reflux disease, and upper airway conditions, and that it

75 Laparoscopic procedures for gastroesophageal reflux disease appear to be as effective as those done b

76 lved in the pathogenesis of gastroesophageal reflux disease are complex and multifactorial.

77 ation rate and incidence of gastroesophageal reflux disease are concerning.

78 regarding the treatment of gastroesophageal reflux disease are developed, based on a review of studi

79 Typical symptoms of gastroesophageal reflux disease are heartburn and regurgitation.

80 pharmacologic strategies in the treatment of reflux disease are highlighted.

81 nd has focused attention on gastroesophageal reflux disease as a causative factor in this shift.

82 f gastric disorders such as gastroesophageal reflux disease, autoimmune gastritis, gastric cancer, an

83 have been identified-mainly gastroesophageal reflux disease, Barrett's esophagus, obesity, and tobacc

84 assessed 100 patients with gastroesophageal reflux disease before and after sphincter augmentation.

85 e and effective therapy for gastroesophageal reflux disease, but its effect on the LES has not been e

86 s frequently mimic those of gastroesophageal reflux disease, but the diseases are distinct in their h

87 of a confirmed diagnosis of gastroesophageal reflux disease by an abnormal esophageal pH study (body

88 ar-old men with symptoms of gastroesophageal reflux disease by Cytosponge is cost effective and would

89 that is distinguished from gastroesophageal reflux disease by the expression of a unique esophageal

90 r place in the treatment of gastroesophageal reflux disease can be determined.

91 acid entering the mouth in gastro-esophageal reflux disease can cause dental erosion.

92 in the small subset of patients with severe reflux disease causing a shortened esophagus and strictu

93 e been confirmed in EoE and gastroesophageal reflux disease cell cultures.

94 Risk factors include gastroesophageal reflux disease, central obesity, and smoking.

95 Gastroesophageal reflux disease complicated by Barrett esophagus (BE) is

96 Gastroesophageal reflux disease complicated by Barrett's esophagus (BE) i

97 se of these technologies in gastroesophageal reflux disease continues to accelerate, and the last 2 y

98 nterval [CI]: 1.04-2.67) or gastroesophageal reflux disease controls (OR = 1.61; 95% CI: 1.33-1.96).

99 oesophageal reflux disease (gastroesophageal reflux disease controls, n = 1332), and population-based

100 chest pain associated with gastroesophageal reflux disease, correlates abnormal ambulatory pH monito

101 , regurgitation, dysphagia, gastroesophageal reflux disease, cough, aspiration, laryngitis, GERD, GOR

102 , regurgitation, dysphagia, gastroesophageal reflux disease, cough, aspiration, laryngitis, GERD, GOR

103 ssive surgical treatment of gastroesophageal reflux disease decreases the rate of bronchiolitis and i

104 te chronic tissue injury in gastroesophageal reflux disease differentially affects mechanosensitive a

105 rugs (lipid-lowering drugs, gastroesophageal reflux disease drugs, antihypertensive drugs, sleep aids

106 sses (lipid-lowering drugs, gastroesophageal reflux disease drugs, diabetes drugs, antihypertensive d

107 as functional dyspepsia and gastroesophageal reflux disease (e.g. vomiting, disordered lower esophage

108 n the last 2 years for many gastroesophageal reflux disease endotherapies, providing some insight int

109 e (NERD) compared with patients with erosive reflux disease (ERD) or Barrett's esophagus (BE).

110 onse rates compared to patients with erosive reflux disease (ERD); pH metry contributes to GERD diagn

111 l complications of obesity: gastroesophageal reflux disease, erosive esophagitis, Barrett's esophagus

112 Most patients with gastroesophageal reflux disease experience symptomatic relapse after stop

113 In both erosive and non-erosive reflux disease, expression levels of Occludin and ZO-1,-

114 ides a clinical overview of gastroesophageal reflux disease, focusing on diagnosis, treatment, and pr

115 th those from subjects with gastroesophageal reflux disease (gastroesophageal reflux disease controls

116 e interval [CI], 2.9-12.9), gastroesophageal reflux disease (GERD) (RR, 1.9; 95% CI, 1.4-2.6), dyspep

117 thophysiological factor in gastro-esophageal reflux disease (GERD) and as a target for GERD treatment

118 ghrelin are associated with gastroesophageal reflux disease (GERD) and Barrett's esophagus.

119 incidence and predictors of gastroesophageal reflux disease (GERD) and dyspepsia and their associatio

120 tential association between gastroesophageal reflux disease (GERD) and extraesophageal manifestations

121 ner to the understanding of gastroesophageal reflux disease (GERD) and its complications.

122 an alternative treatment of gastroesophageal reflux disease (GERD) and may provide durable reflux con

123 ential for the treatment of gastroesophageal reflux disease (GERD) and other esophagogastric diseases

124 the Montreal definition of gastroesophageal reflux disease (GERD) and the Rome III definition of fun

125 sophageal manifestations of gastroesophageal reflux disease (GERD) and to compare the most recent tec

126 ion of the cardia indicates gastroesophageal reflux disease (GERD) and/or is a manifestation of panga

127 recipients with documented gastroesophageal reflux disease (GERD) are at increased risk for graft dy

128 urrent diagnostic tests for gastroesophageal reflux disease (GERD) are suboptimal and do not accurate

129 ia who were thought to have gastroesophageal reflux disease (GERD) but who did not respond to medical

130 Management of gastroesophageal reflux disease (GERD) commonly starts with an empiric tr

131 a minority of patients with gastroesophageal reflux disease (GERD) develop Barrett's esophagus.

132 d; 70% had been treated for gastroesophageal reflux disease (GERD) during infancy.

133 However, gastroesophageal reflux disease (GERD) has remained the most common esoph

134 iding physicians diagnose gastro-oesophageal reflux disease (GERD) have not been evaluated in terms o

135 anges associated with acute gastroesophageal reflux disease (GERD) have not been studied prospectivel

136 r pH monitoring documented Gastro-Esophageal Reflux Disease (GERD) in 53.4% of patients.

137 as to compare recurrence of gastroesophageal reflux disease (GERD) in children randomized to laparosc

138 ly used in the treatment of gastroesophageal reflux disease (GERD) in children; however, their effica

139 cation for the treatment of gastroesophageal reflux disease (GERD) in comparison with a sham procedur

140 Information about gastro-oesophageal reflux disease (GERD) in patients with Diabetes mellitus

141 Symptoms of gastro-esophageal reflux disease (GERD) in pregnancy are reported with a p

142 se or eliminate features of gastroesophageal reflux disease (GERD) in some patients whose symptoms pe

143 Gastroesophageal reflux disease (GERD) is a chronic disorder that affects

144 Gastroesophageal reflux disease (GERD) is a common diagnosis in infants a

145 Gastrointestinal reflux disease (GERD) is a common disorder that negative

146 Gastroesophageal reflux disease (GERD) is a common medical problem in the

147 Severe gastroesophageal reflux disease (GERD) is a lifelong problem that can be

148 Gastroesophageal reflux disease (GERD) is a risk factor for adenocarcinom

149 It has been suggested that gastroesophageal reflux disease (GERD) is a risk factor for developing rh

150 Gastroesophageal reflux disease (GERD) is a very common disorder that aff

151 Gastroesophageal reflux disease (GERD) is associated with impaired epithe

152 The pathogenesis of gastroesophageal reflux disease (GERD) is complex and involves changes in

153 As the economic burden of gastroesophageal reflux disease (GERD) is largely weighted to maintenance

154 he Montreal classification, gastroesophageal reflux disease (GERD) is much more than heartburn and pa

155 Gastroesophageal reflux disease (GERD) is prevalent worldwide, particular

156 I) therapy in patients with gastroesophageal reflux disease (GERD) is reported in up to 40%.

157 Gastro-esophageal reflux disease (GERD) is suggested to be associated with

158 Gastroesophageal reflux disease (GERD) is the most common gastrointestina

159 Gastroesophageal reflux disease (GERD) is the most prevalent gastrointest

160 Gastroesophageal reflux disease (GERD) is the strongest known risk factor

161 lori in the pathogenesis of gastroesophageal reflux disease (GERD) is unknown.

162 iteria included symptoms of gastroesophageal reflux disease (GERD) more than once a month, use of med

163 Many individuals with gastroesophageal reflux disease (GERD) never visit their general practiti

164 cid peptic disorder such as gastroesophageal reflux disease (GERD) nor should it preclude a diagnosis

165 y used for the treatment of gastroesophageal reflux disease (GERD) or completing Heller's myotomy and

166 Treatment-refractory gastro-oesophageal reflux disease (GERD) remains a significant problem in t

167 Most patients with gastroesophageal reflux disease (GERD) report that stress exacerbates the

168 It has been speculated that gastroesophageal reflux disease (GERD) represents a risk factor for the o

169 ed for use in patients with gastroesophageal reflux disease (GERD) symptoms despite proton pump inhib

170 ects a higher prevalence of gastroesophageal reflux disease (GERD) symptoms or a higher degree of eso

171 ity of NBI in patients with gastroesophageal reflux disease (GERD) symptoms.

172 The prevalence of gastro-esophageal reflux disease (GERD) varies widely around the world.

173 Patients with gastroesophageal reflux disease (GERD) who are not responding to proton p

174 re matched to subjects with gastroesophageal reflux disease (GERD) without Barrett's esophagus and to

175 f objective measurements of gastroesophageal reflux disease (GERD) would improve management of patien

176 ia, 1.8; constipation, 3.9; gastroesophageal reflux disease (GERD), 9.7.

177 Gastroesophageal reflux disease (GERD), a condition commonly encountered

178 ease (CrD), celiac disease, gastroesophageal reflux disease (GERD), and eosinophilic esophagitis (EoE

179 table bowel syndrome (IBS), gastroesophageal reflux disease (GERD), and overactive bladder syndrome (

180 ysfunction syndrome (RUDS), gastroesophageal reflux disease (GERD), and rare cases of inflammatory pu

181 r three common indications: gastroesophageal reflux disease (GERD), Barrett's esophagus (BE), and non

182 proposed for patients with gastroesophageal reflux disease (GERD), but there is little evidence of i

183 pylori may protect against gastrointestinal reflux disease (GERD), but these results could be due to

184 ation and for patients with gastroesophageal reflux disease (GERD), diabetes mellitus, depression, an

185 Gastroesophageal reflux disease (GERD), functional dyspepsia (FD) and irr

186 ysiological states, such as gastroesophageal reflux disease (GERD), functional dyspepsia and, possibl

187 tion of body mass index and gastroesophageal reflux disease (GERD), including its complications (esop

188 sophagus, a complication of gastroesophageal reflux disease (GERD), predisposes patients to esophagea

189 previous fundoplication for gastroesophageal reflux disease (GERD), underwent reoperative surgery.

190 Unlike gastroesophageal reflux disease (GERD), whose symptoms closely overlap wi

191 ology-based definitions of gastro-esophageal reflux disease (GERD).

192 medical disorders including gastroesophageal reflux disease (GERD).

193 diagnosis and management of gastroesophageal reflux disease (GERD).

194 estinal disorders (FGD) and gastroesophageal reflux disease (GERD).

195 opy-based interventions for gastroesophageal reflux disease (GERD).

196 crease in the prevalence of gastroesophageal reflux disease (GERD).

197 has centered on surgery for gastroesophageal reflux disease (GERD).

198 esophageal manifestation of gastroesophageal reflux disease (GERD).

199 s omeprazole monotherapy in gastroesophageal reflux disease (GERD).

200 report typical symptoms of gastroesophageal reflux disease (GERD).

201 as altered in patients with gastroesophageal reflux disease (GERD).

202 g patients with symptomatic gastroesophageal reflux disease (GERD).

203 distention in patients with gastroesophageal reflux disease (GERD).

204 n the surgical treatment of gastroesophageal reflux disease (GERD).

205 (CNF) for the treatment of gastroesophageal reflux disease (GERD).

206 tory drugs) and symptoms of gastroesophageal reflux disease (GERD).

207 r patients with early-stage gastroesophageal reflux disease (GERD).

208 ice for obese patients with gastroesophageal reflux disease (GERD).

209 r both BE and EA is chronic gastroesophageal reflux disease (GERD).

210 eatment-naive patients with gastroesophageal reflux disease (GERD).

211 mplications, postoperative gastro-esophageal reflux disease (GERD).

212 for diagnosing adults with gastroesophageal reflux disease (GERD).

213 were dysphagia (70.1%) and gastroesophageal reflux disease (GERD)/heartburn (27.1%).

214 treatment of patients with gastroesophageal reflux disease (GERD); similarly, laparoscopic technique

215 o included 10 patients with gastroesophageal reflux disease (GERD; age, 32-60 y; 7 women) without tro

216 ere matched to persons with gastroesophageal reflux disease (GERD; n = 316) and to population control

217 ntified domains (dysphagia, gastroesophageal reflux disease [GERD], nausea/vomiting, and pain) align

218 toms and the aetiology of gastro-oesophageal reflux disease (GORD) remains unclear.

219 ardia, the contributions of gastroesophageal reflux disease, H. pylori infection, and other factors t

220 in pediatric patients with gastroesophageal reflux disease have shown good to excellent results; how

221 in patients with normal GE (Gastroesophageal Reflux Disease Health-Related Quality of Life score 18.2

222 mptom that can be caused by gastroesophageal reflux disease; however, treatment outcome has been diff

223 degenerative joint disease, gastroesophageal reflux disease, hypertension, urinary stress incontinenc

224 c antireflux surgery due to gastroesophageal reflux disease in adults (>18 years).

225 associated with symptoms of gastroesophageal reflux disease in both normal-weight and overweight wome

226 in meters - and symptoms of gastroesophageal reflux disease in persons of normal weight has not been

227 cidic environment caused by gastroesophageal reflux disease in the gastroesophageal junction and asso

228 ic approach to patients with extraesophageal reflux disease involved the use of insensitive tools, wh

229 Extraesophageal reflux disease is a common clinical presentation to gast

230 Gastroesophageal reflux disease is a common clinical problem.

231 Gastroesophageal reflux disease is a highly prevalent chronic condition i

232 Gastroesophageal reflux disease is a highly prevalent disease.

233 Gastro-oesophageal reflux disease is a potential risk factor for the develo

234 Gastroesophageal reflux disease is a prevalent disorder that often requir

235 the pathogenesis of heartburn in nonerosive reflux disease is a reaffirmation of the definition of r

236 Gastroesophageal reflux disease is common in adults of all ages, but its

237 t of the pathophysiology of gastroesophageal reflux disease is constructed.

238 hagus epithelium related to gastroesophageal reflux disease, is the strongest known risk factor for t

239 ough heartburn is the most common symptom of reflux disease, it is unclear whether the severity of he

240 on "Endoscopic Therapy for Gastroesophageal Reflux Disease." It was approved by the Clinical Practic

241 apies have emerged to treat gastroesophageal reflux disease itself.

242 e esophagus associated with gastroesophageal reflux disease may result in sensitization of afferent p

243 s (asthma, sinusitis, and gastro-oesophageal reflux disease), mental health disorders (depression, po

244 for an esophageal etiology-gastroesophageal reflux disease, motility abnormalities, or esophageal hy

245 rcinogen treatment leads to gastroesophageal reflux disease, multilayered epithelium (MLE, a presumed

246 lication for PPI-refractory gastroesophageal reflux disease (n = 14 270 degrees LPF vs. n = 28 360 de

247 ere matched to persons with gastroesophageal reflux disease (n = 308) without Barrett's esophagus and

248 indeterminate EoE (n = 15), gastroesophageal reflux disease (n = 7), or normal esophagus (n = 21).

249 symptom control in patients with non-erosive reflux disease (NERD) after 6 months.

250 t symptom burden in patients with nonerosive reflux disease (NERD) compared with patients with erosiv

251 Patients with non erosive reflux disease (NERD) have lower response rates compared

252 To analyse the concept of nonerosive reflux disease (NERD), examining its evolving definition

253 h improved understanding of gastroesophageal reflux disease, newer developments in diagnostic techniq

254 , including rhinosinusitis, gastroesophageal reflux disease, obesity and dysfunctional breathing.

255 cter (LES) in patients with gastroesophageal reflux disease often has a low resting pressure and a sh

256 orically distinguished from gastroesophageal reflux disease on the basis of histology and lack of res

257 hen excluding patients with gastrointestinal reflux disease or functional dyspepsia.

258 proton pump inhibitors for gastroesophageal reflux disease or in patients with any of the nongastroi

259 indeterminate EoE) but not gastroesophageal reflux disease or normal esophagus and was correlated to

260 apy in patients with severe gastroesophageal reflux disease or the Zollinger-Ellison syndrome.

261 ry of peptic ulcer disease, gastroesophageal reflux disease, or gastrointestinal bleeding, and prior

262 This article is a review of gastroesophageal reflux disease, other types of esophagitis, benign and m

263 le score <9 (p = .021), and gastroesophageal reflux disease (p = .033).

264 We randomly assigned 64 gastroesophageal reflux disease patients to radiofrequency energy deliver

265 on for selected symptomatic gastroesophageal reflux disease patients who are intolerant of, or desire

266 Too much acid can lead to gastroesophageal reflux disease, peptic ulcer disease, and stress-related

267 eosinophilic bronchitis, gastro-oesophageal reflux disease, postnasal drip syndrome or rhinosinusiti

268 a >50% improvement in their gastroesophageal reflux disease quality of life score (n = 19 [61%] vs. n

269 objective is to evaluate the ability of the Reflux Disease Questionnaire (RDQ) to identify GERD acco

270 ary outcome was symptom control evaluated by Reflux Disease Questionnaire and Reflux Symptom Index.

271 symptoms where based on the use of validated reflux-disease questionnaire (RDQ).

272 pter reviews the biology of gastroesophageal reflux disease, relating pathophysiology to medical and

273 Endoscopic therapies for gastroesophageal reflux disease represent a minimally invasive alternativ

274 vely high rate of recurrent gastroesophageal reflux disease requiring treatment, diminishing some of

275 f non-drug treatments for gastro-oesophageal reflux disease, safety of long-term drug treatment, and

276 igated whether patients with supraesophageal reflux disease (SERD) have impaired UES and esophageal b

277 ence of anxiety, headaches, gastroesophageal reflux disease, sleep apnea, and infections of the respi

278 fied version of a validated gastroesophageal reflux disease-specific QOL tool to patients before and

279 ty of life, measured by the gastroesophageal reflux disease-specific QOL tool, and recurrence, define

280 ) had objective findings of gastroesophageal reflux disease, such as esophagitis.

281 proved in group A, with the Gastroesophageal Reflux Disease Symptom Assessment Scale score decreasing

282 very significantly improved gastroesophageal reflux disease symptoms and quality of life compared wit

283 ue in patients with chronic gastroesophageal reflux disease symptoms is of unproven value, and recomm

284 y for patients with chronic gastroesophageal reflux disease symptoms to assess for Barrett's esophagu

285 d Kingdom with histories of gastroesophageal reflux disease symptoms, assuming the prevalence of Barr

286 rs in patients with chronic gastroesophageal reflux disease that involves recurring cycles of inflamm

287 Triggered by gastroesophageal reflux disease, the origin of this metaplasia remains un

288 pertension, hyperlipidemia, gastroesophageal reflux disease, thyroid disease, diabetes, osteoporosis)

289 tly cleared new endoluminal gastroesophageal reflux disease treatments; however, no controlled trials

290 The history of gastroesophageal reflux disease was highly prevalent in patients who deve

291 Gastroesophageal reflux disease was identified as an important risk facto

292 De novo gastroesophageal reflux disease was reported in 43.8%.

293 nocturnal heartburn due to gastroesophageal reflux disease, was approved by the US Food and Drug Adm

294 Markers of gastroesophageal reflux disease were compared between groups (i.e., lower

295 relating to both asthma and gastroesophageal reflux disease were retrieved.

296 uamous epithelium caused by gastroesophageal reflux disease, whereas intestinal metaplasia in the dis

297 Except for gastroesophageal reflux disease, which showed a higher resolution rate af

298 Patients with gastroesophageal reflux disease who have a partial response to proton-pum

299 isits annually, followed by gastroesophageal reflux disease, with 4.5 million visits.

300 (BEAC) is a complication of gastroesophageal reflux disease, with no effective chemotherapy and poor